BSc3094 is a potent Tau aggregation inhibitor that demonstrates the potential for Alzheimer's disease (AD) research.

BSc3094 (3 mg/kg; i.v.) direct intraventricular administration reduces sarkosyl-insoluble Tau[1]. BSc3094 (0.075~1.5 mM; intraventricular administration) reduces the levels of sarkosyl-insoluble Tau in cortical extracts by ≈70%[1]. BSc3094 reverses the pre-synaptic impairment in organotypic hippocampal slices from pro-aggregant mice, by reversing the pairedpulse depression observed in non-treated pro-aggregant Tau slices after applying a paired-pulse stimulus of the Schaffer collaterals. BSc3094 reverses the increase in Tau phosphorylation levels in rTg4510 mice down to control level. BSc3094 partially reversed the memory deficits in rTg4510 mice[1]. Animal Model: Mice[1]Dosage: 3 mg/kg Administration: I.v. Result: Direct intraventricular administration reduced sarkosyl-insoluble Tau. Animal Model: rTg4510 mice[1]Dosage: 0.075~1.5 mM Administration: Intraventricular administration Result: Reduced the levels of sarkosyl-insoluble Tau in cortical extracts by ≈70%.